NYSE: SOLV
Solventum Revenue

Solventum revenue was N/A for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2024) ending on Sep 30, 2024 was $2.1B, up 0% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, SOLV annual revenue was $8.2B, with 0.8% growth year-over-year.

SOLV revenue history

Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%

Be the first to know when SOLV announces revenue.

SOLV Revenue History By Year

SOLV Yearly RevenueSOLV RevenueSOLV ChangeSOLV Revenue Growth
2023-12-31$8.20B$67.00M+0.82%
2022-12-31$8.13B-$41.00M-0.50%
2021-12-31$8.17BN/AN/A

1 of 1

Solventum Revenue FAQ

What was SOLV's revenue last quarter?

Solventum (NYSE: SOLV) reported Q3 2024 revenue of $2.08 billion up 0.39% year over year. In the same quarter last year, Solventum's revenue was $2.07 billion.

What was Solventum's revenue in 2023?

Solventum's annual revenue for the twelve months ending Dec 31, 2023 was $8.20 billion, a 0.82% increase year over year.

How much does Solventum make in a day?

Based on Solventum annual revenue for the past two years, SOLV makes an average of $22,365,753.42 per day.

What was Solventum's annual revenue growth in the past year?

As of Q1 2025, Solventum's revenue has grown null year over year. Solventum's revenue in the past year totaled N/A.

How much does Solventum make in a year?

Solventum's revenue by year for the past two years is:
  • Solventum's revenue for the twelve months ending Dec 31, 2023 was $8.20 billion, a 0.82% increase year over year.
  • Solventum's annual revenue for Dec 31, 2022 was $8.13 billion, a 0.5% decrease from 2021.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.